Author pages are created from data sourced from our academic publisher partnerships and public sources.
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- A. Drilon, T. Laetsch, +35 authors D. Hyman
- The New England journal of medicine
- 21 February 2018
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective… Expand
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
BACKGROUND BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in… Expand
Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer
There is an urgent need for blood-based, noninvasive molecular tests to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are… Expand
Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study
- C. Baik, G. Strauss, F. Speizer, D. Feskanich
- Cancer Epidemiology, Biomarkers & Prevention
- 25 August 2010
Background: There is increasing evidence suggesting that female hormones may play a significant role in lung cancer development. We evaluated the associations between reproductive factors, exogenous… Expand
Non‐steroidal anti‐inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative
- T. Brasky, J. Liu, +10 authors J. Wactawski-Wende
- International journal of cancer
- 15 October 2014
The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) has been associated with reduced risks of cancers at several sites in some studies; however, we recently reported no association between… Expand
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
9008Background: RET fusions are targetable oncogenic drivers in up to 2% of NSCLC, yet no selective RET inhibitors are approved. BLU-667 is an investigational highly potent and selective RET inhibi...
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer…
8509Background: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts ...
Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological… Expand
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.
- C. Baik, D. Wu, C. Smith, R. Martins, C. Pritchard
- Journal of thoracic oncology : official…
- 1 October 2015
®e report an epidermal growth factor receptor (EGFR) tandem kinase domain duplication (TKD-EGFR) mutation in a non–small-cell lung cancer (NSCLC) patient who had a greater than 10-year response to… Expand
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Brain metastases (BM) occur frequently in many cancers, particularly non-small cell lung cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with poor prognosis and has… Expand